GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies for serious neurodevelopmental disorders, today announced that it has dosed the first patient in its global ...

Drugs that act on NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment consciousness, are key for treating neuropsychiatric disorders. These drugs were ...

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).

A new study suggests a potential molecular strategy for treating fragile X syndrome, an inherited neurodevelopmental disorder that causes autism spectrum disorder and intellectual disability. This ...

GRIN Therapeutics begins patient dosing in global phase 3 Beeline trial of investigational radiprodil for GRINRelated neurodevelopmental disorder: New York Monday, January 12, 202 ...

In a recent study published in Nature, researchers developed the MK-801 bimodal drug that successfully cures obesity, hyperglycemia, and dyslipidemia in mouse models of metabolic illness by combining ...

The FDA approved combination dextromethorphan and bupropion extended-release tablets (Auvelity) for adults with major depressive disorder (MDD), Axsome Therapeutics announced on Friday.

Viruses. Current Pharmaceutical Design, 25(43),4579-88. 7. Wang, H.* (2022). COVID-19, Anti-NMDA Receptor Encephalitis and MicroRNA. Fronters in Immunology, 13:825103.

This is a preview. Log in through your library . Abstract The unconventional N-methyl-D-aspartate (NMDA) receptor subunits GluN3A and GluN3B can, when associated with the other glycine-binding subunit ...

Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and Vigonvita Shanghai Co. Ltd. have described NMDA and serotonin ...